Onconetix Acquires 100% Equity of Realbotix
Onconetix (ONCO) and Realbotix LLC (XBOTF) announced the signing of a definitive share exchange agreement pursuant to which Onconetix will acquire 100% of the issued and outstanding equity interests of Realbotix in an all-stock transaction. The company said, "Realbotix is Realbotix Corp's subsidiary that is focused on researching, designing, building and manufacturing AI-powered, highly customizable humanoid robotics. The robots are used for customer-facing roles in industries such as healthcare, education, hospitality and entertainment. Realbotix is a leader in embodied and physical AI with its patented technologies enabling lifelike expressions, vision, and social interaction. Its robots are known for their highly realistic human appearance and human-centric AI models. Realbotix robots are unique in their ability to operate autonomously via various AI platforms and do not require teleopertions from a human." Upon closing of the proposed transaction, Onconetix will acquire all the issued and outstanding equity interests of Realbotix in exchange for newly issued shares of common stock of Onconetix. Immediately following the closing of the transaction, Realbotix Parent will own between 75% and 90% of the fully diluted common shares of the combined company, depending upon Onconetoix's cash pooistion at closing. Mr. Kiguel will become the CEO of the combined company following closing. The transaction, which has been unanimously approved by the boards of directors of both Onconetix and Realbotix Parent, is subject to customary closing conditions, including approval by Onconetix shareholders, receipt of required regulatory approvals, including applicable securities law clearances in the United States and Canada, and other customary conditions. The transaction is expected to close in the second half of 2026, and the combined company is expected to trade on Nasdaq.
